Search Results - "LUSHER, J"

On the performance of WENO/TENO schemes to resolve turbulence in DNS/LES of high‐speed compressible flows by Hamzehloo, Arash, Lusher, David J., Laizet, Sylvain, Sandham, Neil D.

“…Summary High‐speed compressible turbulent flows typically contain discontinuities and have been widely modeled using Weighted Essentially Non‐Oscillatory…”
Get full text

Numerical Study of Compressible Wall-Bounded Turbulence - the Effect of Thermal Wall Conditions on the Turbulent Prandtl Number in the Low-Supersonic Regime by Lusher, David J., Coleman, Gary N.

“…Direct numerical simulation is used to determine the turbulent Prandtl number  above cold (isothermal) and hot (adiabatic) walls in a family of low-supersonic…”
Get full text

Standardization of thromboelastography: a report from the TEG-ROTEM working group by CHITLUR, M., SORENSEN, B., RIVARD, G. E., YOUNG, G., INGERSLEV, J., OTHMAN, M., NUGENT, D., KENET, G., ESCOBAR, M., LUSHER, J.

“…Laboratory evaluation of bleeding disorders has been performed with the standard clotting assays such as the PT and PTT for several decades. Our improved…”
Get full text

Inhibitors in factor IX deficiency a report of the ISTH-SSC international FIX inhibitor registry (1997-2006) by CHITLUR, M., WARRIER, I., RAJPURKAR, M., LUSHER, J. M.

“…Haemophilia B is an X‐linked disorder resulting in coagulation factor IX deficiency. Patients with severe deficiency (<1% factor IX activity) may have…”
Get full text

Complications of haemophilia in babies (first two years of life): a report from the Centers for Disease Control and Prevention Universal Data Collection System by Kulkarni, R., Presley, R. J., Lusher, J. M., Shapiro, A. D., Gill, J. C., Manco‐Johnson, M., Koerper, M. A., Abshire, T. C., DiMichele, D., Hoots, W. K., Mathew, P., Nugent, D. J., Geraghty, S., Evatt, B. L., Soucie, J. M.

“…Aim To describe the prevalence and complications in babies ≤2 years with haemophilia. Methods We used a standardized collection tool to obtain consented data…”
Get full text

Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis by White, 2nd, G C, Rosendaal, F, Aledort, L M, Lusher, J M, Rothschild, C, Ingerslev, J

Get more information

Molecular pathogenesis and heterogeneity in type 3 VWD families in U.S. Zimmerman program by Christopherson, Pamela A., Haberichter, Sandra L., Flood, Veronica H., Perry, Crystal L., Sadler, Brooke E., Bellissimo, Daniel B., Di Paola, Jorge, Montgomery, Robert R., Abshire, T, Weiler, H, Lillicrap, D, James, P, O’Donnell, J, Ng, C, Bennett, C, Sidonio, R, Manco‐Johnson, M, Journeycake, J, Zia, A, Lusher, J, Rajpurkar, M, Shapiro, A, Lentz, S, Gill, J, Leissinger, C, Ragni, M, Tarantino, M, Roberts, J, Hord, J, Strouse, J, Ma, A, Valentino, L, Boggio, L, Sharathkumar, A, Gruppo, R, Kerlin, B, Kulkarni, R, Green, D, Hoots, K, Brown, D, Mahoney, D, Mathias, L, Bedros, A, Diamond, C, Neff, A, DiMichele, D, Giardina, P, Cohen, A, Paidas, M, Werner, E, Matsunaga, A, Shafer, F, Konkle, B, Cuker, A, Kouides, P, Stein, D

“…Background Type 3 von Willebrand Disease (VWD) is a rare and severe form of VWD characterized by the absence of von Willebrand factor (VWF). Objectives As part…”
Get full text

3D-e-Chem-VM: Structural Cheminformatics Research Infrastructure in a Freely Available Virtual Machine by McGuire, Ross, Verhoeven, Stefan, Vass, Márton, Vriend, Gerrit, de Esch, Iwan J. P, Lusher, Scott J, Leurs, Rob, Ridder, Lars, Kooistra, Albert J, Ritschel, Tina, de Graaf, Chris

“…3D-e-Chem-VM is an open source, freely available Virtual Machine (http://3d-e-chem.github.io/3D-e-Chem-VM/) that integrates cheminformatics and bioinformatics…”
Get full text

Laboratory variability in the diagnosis of type 2 VWD variants by DiGiandomenico, Stefanie, Christopherson, Pamela A., Haberichter, Sandra L., Abshire, Thomas C., Montgomery, Robert R., Flood, Veronica H., Valentino, L., Abshire, T., Dunn, A., Bennett, C., Lusher, J., Rajpurkar, M., Hoots, W. K., Brown, D., Shapiro, A., Paola, J. Di, Lentz, S., Gill, J., Leissinger, C., Ragni, M., Hord, J., Manco‐Johnson, M., Ma, A., Boggio, L., Sharathkumar, A., Gruppo, R., Kerlin, B., Journeycake, J., Kulkarni, R., Mahoney, D, Mathias, L., Bedros, A., Diamond, C., Neff, A., Paroskie, A., DiMichele, D., Giardina, P., Cohen, A., Paidas, M., Werner, E., Matsunaga, A., Singer, T., Tarantino, M., Roberts, J., Shafer, F., Konkle, B., Cuker, A., Kouides, P., Stein, D., Manco‐Johnson, M., Dunn, A., Bennett, C., Journeycake, J., Lusher, J., Rajpurkar, M., Shapiro, A., Lentz, S., Lillicrap, D., James, P., Leissinger, C., Roberts, J., Ragni, M.

“…Essentials Patients with von Willebrand disease were enrolled in our study. Type 2 VWD diagnoses were based on original test results. Repeat evaluation…”
Get full text

Development and introduction of recombinant factor VIII - a clinician's experience by LUSHER, J. M.

Get full text

Thromboelastography identifies children with rare bleeding disorders and predicts bleeding phenotype by Zia, A. N., Chitlur, M., Rajpurkar, M., Ozgonenel, B., Lusher, J., Callaghan, J. H., Callaghan, M. U.

“…Summary Rare bleeding disorders (RBDs) comprise 3–5% of all congenital bleeding disorders. They can evade typical coagulation screening tests and there is a…”
Get full text

Prophylactic therapy with Fibrogammin® P is associated with a decreased incidence of bleeding episodes: a retrospective study by LUSHER, J., PIPE, S. W., ALEXANDER, S., NUGENT, D.

“…Congenital factor XIII (FXIII) deficiency is an extremely rare, yet potentially life‐threatening, bleeding disorder, with a 30% rate of spontaneous…”
Get full text

Sites of initial bleeding episodes, mode of delivery and age of diagnosis in babies with haemophilia diagnosed before the age of 2 years: a report from The Centers for Disease Control and Prevention's (CDC) Universal Data Collection (UDC) project by KULKARNI, R., SOUCIE, J. M., LUSHER, J., PRESLEY, R., SHAPIRO, A., GILL, J., MANCO-JOHNSON, M., KOERPER, M., MATHEW, P., ABSHIRE, T., DIMICHELE, D., HOOTS, K., JANCO, R., NUGENT, D., GERAGHTY, S., EVATT, B.

“…Lack of detailed natural history and outcomes data for neonates and toddlers with haemophilia hampers the provision of optimal management of the disorder. We…”
Get full text

Structural Basis for Agonism and Antagonism for a Set of Chemically Related Progesterone Receptor Modulators by Lusher, Scott J., Raaijmakers, Hans C.A., Vu-Pham, Diep, Dechering, Koen, Lam, Tsang Wai, Brown, Angus R., Hamilton, Niall M., Nimz, Olaf, Bosch, Rolien, McGuire, Ross, Oubrie, Arthur, de Vlieg, Jacob

“…The progesterone receptor is able to bind to a large number and variety of ligands that elicit a broad range of transcriptional responses ranging from full…”
Get full text

Dopamine D4 receptor gene (DRD4) is associated with Novelty Seeking (NS) and substance abuse : the saga continues by LUSHER, J. M, CHANDLER, C, BALL, D

Get full text

Clinical evaluation of moroctocog alfa (AF-CC), a new generation of B-domain deleted recombinant factor VIII (BDDrFVIII) for treatment of haemophilia A: demonstration of safety, efficacy, and pharmacokinetic equivalence to full-length recombinant factor VIII by RECHT, M., NEMES, L., MATYSIAK, M., MANCO-JOHNSON, M., LUSHER, J., SMITH, M., MANNUCCI, P., HAY, C., ABSHIRE, T., O'BRIEN, A., HAYWARD, B., UDATA, C., ROTH, D.A., ARKIN, S.

“…BDDrFVIII is a B‐domain deleted recombinant factor VIII (rFVIII) product for haemophilia A. Manufacture uniquely includes purification chromatography by…”
Get full text

Immune tolerance induction in 31 children with haemophilia A: is ITI less successful in African Americans? by CALLAGHAN, M. U., RAJPURKAR, M., CHITLUR, M., WARRIER, I., LUSHER, J.

“…Inhibitor development continues to be a major problem in the treatment of haemophilia. Immune tolerance induction (ITI) continues to be the most effective…”
Get full text

The safety and efficacy of B-domain deleted recombinant factor VIII concentrate in patients with severe haemophilia A by Lusher, J. M., Lee, C. A., Kessler, C. M., Bedrosian, C. L.

“…Background: B‐domain‐deleted recombinant factor VIII (BDDrFVIII) was developed when the B‐domain was found to be redundant for maintaining haemostasis. This…”
Get full text

Is the incidence and prevalence of inhibitors greater with recombinant products? No by Lusher, J. M.

Get full text

Therapeutic and prophylactic ethanol lock therapy in patients with bleeding disorders by Rajpurkar, M., McGrath, E., Joyce, J., Boldt-MacDonald, K., Chitlur, M., Lusher, J.

“…Summary Obtaining a reliable venous access is a limiting factor for early initiation of clotting factor prophylaxis and immune tolerance induction. To…”
Get full text